Quick Answer
HALOZYME THERAPEUTICS, INC. reported Cash and Equivalents of $133.82 million for fiscal year 2025.
HALOZYME THERAPEUTICS, INC. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $133.82M | +15.5% |
| 2024 | $115.85M | -2.1% |
| 2023 | $118.37M | -49.5% |
| 2022 | $234.19M | +97.3% |
| 2021 | $118.72M | -19.6% |
| 2020 | $147.70M | +22.9% |
| 2019 | $120.18M | +107.4% |
| 2018 | $57.94M | -65.7% |
| 2017 | $168.74M | +152.7% |
| 2016 | $66.76M | +54.2% |
| 2015 | $43.29M | -29.5% |
| 2014 | $61.39M | +124.4% |
| 2013 | $27.36M | -72.5% |
| 2012 | $99.50M | +90.0% |
| 2011 | $52.38M | -36.7% |
| 2010 | $82.76M | +22.7% |
| 2009 | $67.46M | +5.9% |
| 2008 | $63.72M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $419.67M | +171.9% | +578.4% |
| June 30, 2025 | $61.86M | -67.1% | -64.9% |
| March 31, 2025 | $176.33M | +7.1% | +52.2% |
| December 31, 2024 | $115.85M | -2.1% | -24.9% |
| September 30, 2024 | $154.32M | -43.7% | -17.9% |
| June 30, 2024 | $187.86M | -15.1% | +14.1% |
| March 31, 2024 | $164.63M | +70.8% | +39.1% |
| December 31, 2023 | $118.37M | -49.5% | -56.8% |
- HALOZYME THERAPEUTICS, INC. showed an increase of +15.5% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2008–2025 period, HALOZYME THERAPEUTICS, INC.’s cash and equivalents has grown by 110.0% (from $63.72 million to $133.82 million).
- The most recent figure is from HALOZYME THERAPEUTICS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: